Rhabdomyolysis as a rare severe complication of statin therapy: differential diagnosis in real clinical practice (a clinical case)

The mechanisms of drug-induced myopathies include direct myotoxicity, immune-mediated and indirect muscle damage. Clinical manifestations range from asymptomatic or minor myalgia and muscle weakness to chronic myopathy with severe weakness and, in rare cases, rhabdomyolysis with release of cellular breakdown products into the bloodstream and intercellular space. Although muscle symptoms are the most common adverse events when using statins, they do not pose a real threat in most cases. Rhabdomyolysis is an extremely rare complication of statin therapy. The case illustrates the difficulties that arose in the differential diagnosis of rhabdomyolysis etiology in a patient receiving high-dose statin therapy. The widespread use of high-intensity statin therapy, often accompanied by the simultaneous use of ticagrelor and proton pump inhibitors, requires caution regarding treatment safety, particularly in elderly patients.

1. Ostrowski P, Bonczar M, Avram AE, et al. Safety monitoring of drug-induced muscle injury and rhabdomyolysis: a biomarker-guided approach for clinical practice and drug trials. Clin Chem Lab Med. 2023;61(10):1688-99. DOI:10.1515/cclm-2023-0313.

2. Mastaglia FL. The changing spectrum of drug-induced myopathies. Acta Myol. 2020;39(4):283-8. DOI:10.36185/2532-1900-031.

3. Janssen L, Allard NAE, Saris CGJ, et al. Muscle toxicity of drugs: when drugs turn physiology into pathophysiology. Physiol Rev. 2020;100(2):633-72. DOI:10.1152/physrev.00002.2019.

4. Stroes ES, Thompson PD, Corsini A, et al.; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapyEuropean Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012-22. DOI:10.1093/eurheartj/ehv043.

5. Dyadyk AI, Kugler TE, Zborowskyy SR, Suliman YuV. Statin-associated muscle symptoms: epidemiology, risk factors, mechanisms and treatment. Kardiologiia. 2019;59(5S):4-12. (In Russ.) DOI:10.18087/cardio.2522.

6. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med. 2005;165(22):2671-6. DOI:10.1001/archinte.165.22.2671.

7. Vinci P, Panizon E, Tosoni LM, et al. Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy. Int J Mol Sci. 2021;22(21):11687. DOI:10.3390/ijms222111687.

8. Davis JW, Weller SC. Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153000 patients. BMJ Open. 2021;11(6):e043714. DOI:10.1136/bmjopen-2020-043714.

9. Sumarokov AB, Chubykina UV, Ezhov MV. Rhabdomyolysis is a rare complication of statin therapy. Case report and literature review. Russian Cardiology Bulletin. 2022;17(1):84-92. (In Russ.) DOI:10.17116/Cardiobulletin20221701184.

10. Tsygankova OV, Evdokimova NE, Bayramova SS, Susekov AV. Statin-induced rhabdomyolysis in a 60-year-old woman with decompensated type 2 diabetes: a case report. Russian Journal of Cardiology. 2021;26(11):4471. (In Russ.) DOI:10.15829/1560-4071-2021-4471.

11. Sychev DA, Ostroumova TM, Ostroumova OD, et al. Statin-Induced Myopathy. Safety and Risk of Pharmacotherapy. 2023;11(3):252-70. (In Russ.) DOI:10.30895/2312-7821-2023-11-3-252-270.

12. Newman CB, Preiss D, Tobert JA, et al.; American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38-e81. DOI:10.1161/ATV.0000000000000073.

13. Sumarokov AB. Autoimmune necrotizing statin-induced myopathy. Journal of Atherosclerosis and Dyslipidemias. 2022;(2):5-9. (In Russ.) DOI:10.34687/2219-8202.JAD.2022.02.0001.

14. Ezhov MV, Kukharchuk VV, Sergienko IV, et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471. (In Russ.) DOI:10.15829/1560-4071-2023-5471.

15. Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-21. DOI:10.1002/cpt.2557.

16. Montastruc JL. Rhabdomyolysis and statins: A pharmacovigilance comparative study between statins. Br J Clin Pharmacol. 2023;89(8):2636-8. DOI:10.1111/bcp.15757.

17. Averkov OV, Harutyunyan GK, Duplyakov DV, et al. 2024 Clinical practice guidelines for Acute myocardial infarction with ST segment elevation electrocardiogram. Russian Journal of Cardiology. 2025;30(3):6306. (In Russ.) DOI:10.15829/1560-4071-2025-6306.

18. Cannon CP, Blazing MA, Giugliano RP, et al. IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387-97. DOI:10.1056/NEJMoa1410489.

19. Rosenson RS, Baker SK, Jacobson TA, et al., The National Lipid Association’s Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3):S58-S71. DOI:10.1016/j.jacl.2014.03.004.

20. Banach M, Rizzo M, Toth PP, et al. Statin intolerance — an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opin Drug Saf. 2015;14(6):935-55. DOI:10.1517/14740338.2015.1039980.

21. Glueck CJ, Lee K, Prince M, et al. Low serum vitamin D, statin associated muscle symptoms, vitamin D supplementation. Atherosclerosis. 2017;256:125-7. DOI:10.1016/j.atherosclerosis.2016.11.027.

22. Roule V, Alexandre J, Lemaitre A, et al. Rhabdomyolysis with Co-Administration of Statins and Antiplatelet Therapies-Analysis of the WHO Pharmacovigilance Database. Cardiovasc Drugs Ther. 2024;38(6):1191-9. DOI:10.1007/s10557-023-07459-8.

23. Bellosta S, Corsini A. Statin drug interactions and related adverse reactions. Expert Opin Drug Saf. 2012;11(6):933-46. DOI:10.1517/14740338.2012.712959.

24. Ohyama K, Iida M, Akiyama S, et al. Time-to-onset Analysis of Rhabdomyolysis due to Different Proton Pump Inhibitors Using a Pharmacovigilance Database. In Vivo. 2024;38(3):1285-91. DOI:10.21873/invivo.13567.

25. Lalatović N, Ždralević M, Antunović T, Pantović S. Genetic polymorphisms in ABCB1 are correlated with the increased risk of atorvastatin-induced muscle side effects: a cross-sectional study. Sci Rep. 2023;13(1):17895. DOI:10.1038/s41598-023-44792-2.

26. Hoenig MR, Walker PJ, Gurnsey C, et al. The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort. J Clin Lipidol. 2011;5(2):91-6. DOI:10.1016/j.jacl.2011.01.001.